HRAS
Reaktivität: Human
WB, PLA
Wirt: Maus
Polyclonal
unconjugated
Applikationshinweise
WB: 1:500-1:3000, IHC-P: 1:100-1:1000, ICC/IF: 1:100-1:1000. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
0.1M Tris, 0.1M Glycine, 20 % Glycerol ( pH 7). 0.01 % Thimerosal was added as a preservative.
Konservierungsmittel
Thimerosal (Merthiolate)
Vorsichtsmaßnahmen
This product contains Thimerosal (Merthiolate): a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C
Informationen zur Lagerung
Keep as concentrated solution. Aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
Basu, Lee, Salotti, Basu, Sakchaisri, Xiao, Walia, Westlake, Morrison, Johnson: "Oncogenic RAS-Induced Perinuclear Signaling Complexes Requiring KSR1 Regulate Signal Transmission to Downstream Targets." in: Cancer research, Vol. 78, Issue 4, pp. 891-908, (2019) (PubMed).
Gao, Wang, Jin, Hu, Duan, Shi, Du, Song, Yang, Li, Han, Zhao, Zhang, Fan, Miao: "Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells." in: Breast cancer research : BCR, Vol. 20, Issue 1, pp. 112, (2018) (PubMed).
Brandt, Albers, Hejhal, Catalano, Wild, Frew: "Oncogenic HrasG12V expression plus knockdown of Cdkn2a using ecotropic lentiviral vectors induces high-grade endometrial stromal sarcoma." in: PLoS ONE, Vol. 12, Issue 10, pp. e0186102, (2017) (PubMed).